Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors

Arthritis and Rheumatism

Volumn 46, Issue 12, 2002, Pages 3159-3167

  Kusunoki, Natsuko ^a   Yamazaki, Ryuta ^b   Kawai, Shinichi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 IODOPHENYL) 3 (4 NITROPHENYL) 5 (2,4 DISULFOPHENYL) 2H TETRAZOLIUM; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; BROXURIDINE; CASPASE INHIBITOR; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DNA FRAGMENT; ETODOLAC; INDOMETACIN; INTERLEUKIN 1BETA; LUCIFERASE; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROFECOXIB; TETRAZOLIUM; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; DNA RESPONSIVE ELEMENT; DRUG EFFECT; FIBROBLAST; HUMAN; HUMAN CELL; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; ARTHRITIS, RHEUMATOID; CELL DIVISION; CELL SURVIVAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; FIBROBLASTS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SULFONAMIDES; SYNOVIAL MEMBRANE; TRANSCRIPTION FACTORS;

EID: 0036898493     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10692     Document Type: Article

References (42)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971;231:232-5.
2. Flower RJ, Gryglewski R, Herbaczynska-Cedro K, Vane JR. Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nature 1972;238:104-6.
3. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991;88:2692-6.
4. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-72.
5. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol 1996;25:9-21.
6. Kawai S. Cyclooxygenase selectivity and the risk of gastrointestinal complications of various non-steroidal anti-inflammatory drugs: A clinical consideration. Inflamm Res 1998;47 Suppl 2:S102-6.
7. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
8. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al, VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
9. Jiang C, Ting AT, Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-6.
10. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor γ in rheumatoid synovial cells. J Pharmacol Exp Ther 2002;302:18-25.
11. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 1998;396:77-80.
12. Nishioka K, Hasunuma T, Kato T, Sumida T, Kobata T. Apotosis in rheumatoid arthritis: A novel pathway in the regulation of synovial tissue. Arthritis Rheum 1998;41:1-9.
13. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000;275:11397-403.
14. Shift SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995;96:491-503.
15. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-58635, celecoxib). J Med Chem 1997;40:1347-65.
16. International Patent Publication WO95/00501.
17. Kato M, Nishida S, Kitasato H, Sakata N, Kawai S. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: Investigation using human peripheral monocytes. J Pharm Pharmacol 2001;53:1679-85.
18. Kawai S, Nishida S, Kato M, Furumaya Y, Okamoto R, Koshino T, et al. Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol 1998;347:87-94.
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
21. Wyllie AH, Kerr JF, Currie AR. Cell death: The significance of apoptosis. Int Rev Cytol 1980;68:251-306.
22. Marcus SL, Miyata KS, Zhang B, Subramani S, Rachubinski RA, Capone JP. Diverse peroxisome proliferator-activated receptors bind to the peroxisome proliferator-responsive elements of the rat hydratase/dehydrogenase and fatty acyl-CoA oxidase genes, but differentially induce expression. Proc Natl Acad Sci U S A 1993;90:5723-7.
23. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPARγ2: Tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994;8:1224-34.
24. Crofford LJ, Wilder RL, Ristimaki AP, Sano H, Remmers EF, Epps HR, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest 1994;93:1095-101.
25. Kobayashi T, Okamoto K, Kobata T, Hasunuma T, Sumida T, Nishioka K. Tumor necrosis factor a regulation of the Fasmediated apoptosis-signaling pathway in synovial cells. Arthritis Rheum 1999;42:519-26.
26. Tsuboi M, Eguchi K, Kawakami A, Matsuoka N, Kawabe Y, Aoyagi T, et al. Fas antigen expression on synovial cells was down-regulated by interleukin 1 beta. Biochem Biophys Res Commun 1996;218:280-5.
27. 2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 2000;106:189-97.
28. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997;272:3406-10.
29. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;324:1946-52.
30. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
31. Δ716 knock-out mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001;61:1733-40.
32. Δ716 knockout mice. Nature Med 2001;7:1048-51.
33. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409-12.
34. Kishimoto Y, Takata N, Jinnai T, Morisawa T, Shiota G, Kawasaki H, et al. Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane. Gut 2000;47:812-9.
35. Goldman AP, Williams CS, Sheng H, Lamps LW, Williams VP, Pairet M, et al. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 1998;19:2195-9.
36. Takahashi M, Fukutake M, Yokota S, Ishida K, Wakabayashi K, Sugimura T. Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2. J Cancer Res Clin Oncol 1996;122:219-22.
37. Yoshimi N, Shimizu M, Matsunaga K, Yamada Y, Fujii K, Hara A, et al. Chemopreventive effect of N-(2-cyclohexyloxy-4-nitrophenyl)-methane sulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, in rat colon carcinogenesis induced by azoxymethane. Jpn J Cancer Res 1999;90:406-12.
38. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
39. Masferrer JL, Koki A, Seibert K. COX-2 inhibitors: A new class of antiangiogenic agents. Ann N Y Acad Sci 1999;889:84-6.
40. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001;15:2742-4.
41. Myers C, Koki A, Pamukcu R, Wechter W, Padley RJ. Proapoptotic anti-inflammatory drugs. Urology 2001;57 Suppl 1:73-6.
42. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272-7.